Abstract

Dilated cardiomyopathy (DCM) is a type of heart disease delimited by enlargement and dilation of one or both of the ventricles along with damaged contractility, which is often accompanied by the left ventricular ejection fraction (LVEF) less than 40%. DCM is progressive and always leads to heart failure. Circular RNAs (circRNAs) are unique species of noncoding RNAs featuring high cell-type specificity and long-lasting conservation, which normally are involved in the regulation of heart failure and DCM recently. So far, a landscape of various single gene or polygene mutations, which can cause complex human cardiac disorders, has been investigated by human-induced pluripotent stem cell (hiPSC) technology. Furthermore, DCM has been modeled as well, providing new perspectives on the disease study at a cellular level. In addition, current genome editing methods can not only repair defects of some genes, but also rescue the disease phenotype in patient-derived iPSCs, even introduce pathological-related mutations into wild-type strains. In this review, we gather up the aspects of the circRNA expression and mechanism in the DCM disease scenario, facilitating understanding in DCM development and pathophysiology in the molecular level. Also, we offer an update on the most relevant scientific progress in iPSC modeling of gene mutation–induced DCM.

Highlights

  • Dilated cardiomyopathy (DCM) is genetically and phenotypically heterogenous, accompanied by left ventricular dilatation and dysfunction

  • Significant efforts have been made in genetic variants–induced pathophysiological changes for human heart diseases such as DCM, HCM, and various types of long QT syndrome (LQTS), our understanding of circRNA function in heart disease is still very limited

  • HRCR decreases the level of ARC expression and enhances myocardial hypertrophy produced by isoproterenol (ISO) via sponging with downregulated MiR-223 (Wang et al, 2016)

Read more

Summary

Cardiomyopathy in Hearts and Pluripotent Stem

Dilated cardiomyopathy (DCM) is a type of heart disease delimited by enlargement and dilation of one or both of the ventricles along with damaged contractility, which is often accompanied by the left ventricular ejection fraction (LVEF) less than 40%. DCM is progressive and always leads to heart failure. Circular RNAs (circRNAs) are unique species of noncoding RNAs featuring high cell-type specificity and long-lasting conservation, which normally are involved in the regulation of heart failure and DCM recently. DCM has been modeled as well, providing new perspectives on the disease study at a cellular level. Current genome editing methods can repair defects of some genes, and rescue the disease phenotype in patient-derived iPSCs, even introduce pathologicalrelated mutations into wild-type strains.

INTRODUCTION
What is DCM?
Mechanism or potential application
Up Up Up Down Down Down
Use of hiPSCs for the Study of circRNAs in DCM
Challenges of hiPSC Modeling and Translational Aspects
Findings
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call